By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, ...

Novo Nordisk has launched its weight-loss drug Wegovy in India, while Eli Lilly's Mounjaro has received regulatory approval, ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

Mounjaro, the weight loss injection developed by pharmaceutical firm Lilly, is set to be prescribed on the NHS for the first ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...